Cytokinetics to Announce Second Quarter Results on August 3, 2023
27 Julho 2023 - 5:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it
is scheduled to report second quarter results on August 3, 2023 at
4:00 PM Eastern Time. Following the announcement, Cytokinetics’
senior management will host a conference call at 4:30 PM Eastern
Time to discuss operational and financial results and the company’s
outlook for the future.
The conference call will be simultaneously
webcast and can be accessed from the Investors & Media section
of Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by
registering in advance at the following link: Cytokinetics Q2 2023
Earnings Conference Call. Upon registration, participants will
receive a dial-in number and a unique passcode to access the call.
An archived replay of the webcast will be available via
Cytokinetics’ website for twelve months.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Aficamten is a next-in-class cardiac
myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3
clinical trial of aficamten in patients with symptomatic
obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also
being evaluated in non-obstructive HCM and the company plans to
begin a Phase 3 trial later this year. Cytokinetics is also
developing omecamtiv mecarbil, a cardiac muscle activator in
patients with heart failure. Additionally, Cytokinetics is
developing CK-136, a cardiac troponin activator for the potential
treatment HFrEF and other types of heart failure, such as right
ventricular failure, resulting from impaired cardiac contractility,
and CK-586, a cardiac myosin inhibitor with a mechanism of action
distinct from aficamten. In 2023, Cytokinetics is celebrating its
25-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane
WeiserSenior Vice President, Corporate Communications, Investor
Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024